Cytek Biosciences, Inc.
NASDAQ:CTKBMedical - Devices
-$0.11 today
- Market cap
- $774.24M
- Beta
- 1.19
- P/E (TTM)
- -6.7
- EPS (TTM)
- -$0.57
Volume 1.05M
Average 0.88M
CTKB Change in Working Capital
Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.
Cytek Biosciences, Inc.NASDAQ: CTKB
Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026
Change in working capital growth accelerates
Q1 FY2026 change in working capital of $9M rose 197.1% year over year, ahead of the +127.2% change in trailing-twelve-month change in working capital. Over 3 fiscal years it compounded at -50.7% a year.
Context
- Change in working capital amounted to 2.4% of revenue in FY2025, down 1.5 pp from a year earlier.
- Change in working capital increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +197.1% holds above the trailing-twelve-month pace of +127.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Change in Working Capital history
USD · from the cash flow
- Latest · FY2025
- (4.79M) USD
- Year-over-year change
- -162.2%
| Period | Period end | Change in Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (4.79M) | -162.2% |
| FY2024 | 2024-12-31 | 7.71M | +173.4% |
| FY2023 | 2023-12-31 | (10.51M) | +73.7% |
| FY2022 | 2022-12-31 | (39.93M) | -361.8% |
| FY2021 | 2021-12-31 | (8.65M) | — |
Change in Working Capital vs competitors
How CTKB compares with its peers on the latest reported figures
- CTKB's LTM Mar 2026 change in working capital of $1.18M is the smallest of the 6 companies compared; the peer median is $87.08M.
- Its year-over-year change of +127.2% is the 3rd highest of 6, against a peer median of +100.1%.
- Change in working capital amounts to 0.6% of revenue for CTKB, versus a peer median of 6.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $288M | +98.6% | -50.5% | 3.9% | |
| LTM Jun 2026 | $214.9M | +100.1% | +0.2% | 6.1% | |
| LTM Mar 2026 | $87.08M | +302.5% | +53.8% | 101.0% | |
| LTM Jun 2026 | $51.58M | +474.0% | — | 8.4% | |
| LTM Jun 2026 | $14.2M | -105.1% | — | 0.5% | |
| LTM Mar 2026 | $1.18M | +127.2% | -50.7% | 0.6% | |
| Peer median (excluding CTKB) | $87.08M | +100.1% | +0.2% | 6.1% | |
Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 3.03M | 2.48M | (12.15M) | (6.02M) | (66.54M) |
| Depreciation & Amortization | 1.24M | 5.66M | 9.23M | 10.49M | 11.98M |
| Deferred Income Tax | 0 | 0 | 0 | (2.89M) | 33.56M |
| Stock-Based Compensation | 6.59M | 16.6M | 22.05M | 26.85M | 24.59M |
| Change in Working Capital | (8.65M) | (39.93M) | (10.51M) | 7.71M | (4.79M) |
| Accounts Receivables | (12.37M) | (19.74M) | (7.33M) | (5.43M) | 368K |
| Inventory | (7.07M) | (17.65M) | 4.29M | 14.76M | (5.24M) |
| Accounts Payables | (256K) | 1.86M | (1.78M) | 2.58M | 448K |
| Other Working Capital | 11.05M | (4.39M) | (5.68M) | (4.2M) | (366K) |
| Other Non-Cash Items | 2.42M | 2.96M | (3.34M) | (10.77M) | (3.47M) |
| Operating Cash Flow | 4.63M | (12.23M) | 5.28M | 25.38M | (4.69M) |
| Capital Expenditures | (4.36M) | (9.87M) | (4.83M) | (3.53M) | (4.08M) |
| Acquisitions (Net) | (16.63M) | 0 | (45.13M) | (471K) | 252K |
| Purchases of Investments | 0 | (46.04M) | (175.94M) | (274.06M) | (278.16M) |
| Sales of Investments | 0 | 0 | 132M | 195M | 292.21M |
| Other Investing Activities | 0 | (120K) | (179K) | 84K | (107K) |
| Investing Cash Flow | (20.99M) | (55.91M) | (93.89M) | (82.97M) | 10.12M |
| Debt Repayment | (2.77M) | 2.93M | (565K) | 3.62M | 837K |
| Common Stock Issued | 215.69M | 2.79M | 0 | 0 | 1.47M |
| Common Stock Repurchased | 0 | 0 | (44.15M) | (21.61M) | (15.07M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 642K | (209K) | 2.9M | 2.17M | (669K) |
| Financing Cash Flow | 213.56M | 5.51M | (41.81M) | (15.82M) | (13.43M) |
| Effect of Forex Changes | 1.3M | (2.49M) | (1.45M) | 4.53M | 109K |
| Net Change in Cash | 198.5M | (65.12M) | (131.87M) | (68.89M) | (7.89M) |
| Free Cash Flow | 266K | (22.1M) | 454K | 21.85M | (8.77M) |
Cytek Biosciences, Inc.
NASDAQ:CTKB
Intrinsic Alpha fair value
Locked
Current Price
$5.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.